A Comprehensive Register Of Lymphoproliferative Disorders (ReLy)

April 2, 2026 updated by: Luca Arcaini, Fondazione IRCCS Policlinico San Matteo di Pavia

The primary objective of this study is to assess the 10-year overall survival (OS) of patients with different lymphoproliferative disorders. Secondary objectives include evaluating the comorbidities and fitness of patients and their impact on treatment choices and outcomes. Additionally, the study will examine the effectiveness of various therapeutic regimens, with a particular focus on new treatments, such as chemo-free protocols, targeted drugs, and cell therapies, in order to determine the best treatment sequence for refractory and relapsed cases.

The research will also investigate how clinical and biological factors influence disease progression or relapse. Another aim is to explore potential correlations between genotype, clinical phenotype, and outcomes, both at diagnosis and during various disease stages. The study will also assess the incidence of tumor lysis syndrome and other adverse events during treatment, considering how these factors might affect treatment discontinuations or dose reductions.

Another objective is to evaluate the outcomes of patients who are managed with a "watch and wait" approach. Long-term toxicities and the occurrence of secondary malignancies will also be studied, alongside the analysis of healthcare costs and the resources used in patient management.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

9000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients ≥ 18 years diagnosed with and/or treated for lymphoproliferative disorders.

Description

Inclusion Criteria:

  • Patients ≥ 18 years diagnosed with and/or treated for lymphoproliferative disorders.
  • Prospective patients (or their or legal guardians) who have the ability to understand and be willing to sign a written informed consent document
  • Retrospective patients who have signed the institutional document allowing the use of their data for research on their disease

Exclusion Criteria:

  • Patients who are unable to understand informed consent document

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
LNH B
malignant tumor of the lymphatic system originating from the uncontrolled proliferation of B lymphocytes,
LNH T/NK
A heterogeneous and rare group of blood cancers (hematological malignancies) that originate from the malignant transformation of mature T lymphocytes or natural killer (NK) cells.
Hodgkin
It is a tumor of the lymphatic system, characterized by the presence of Reed-Sternberg cells, which usually originates in the lymph nodes.
Immunodeficiency-associated
conditions characterized by abnormal lymphoid tissue growth, ranging from benign to malignant lymphomas, resulting from immune dysregulation
Hystiocitic and dendritic cell neoplasms
a rare, heterogeneous group of hematologic malignancies originating from the mononuclear phagocyte system (monocytes, macrophages, and dendritic cells)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
To evaluate 10 year overall survival (OS) of each lymphoproliferative disorder.
Time Frame: from 2002 to 2030
from 2002 to 2030

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 9, 2022

Primary Completion (Estimated)

December 30, 2030

Study Completion (Estimated)

December 30, 2030

Study Registration Dates

First Submitted

April 2, 2026

First Submitted That Met QC Criteria

April 2, 2026

First Posted (Actual)

April 9, 2026

Study Record Updates

Last Update Posted (Actual)

April 9, 2026

Last Update Submitted That Met QC Criteria

April 2, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ReLy

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lymphoproliferative Disease

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe